LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT05786417
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Angina
  • Stable Ischemic Heart Disease

Eligibility Criteria

Sex
ALL
Age
65 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Clinician Discretion — OTHER
    Clinician discretion as to which BB or CCB will be used if the participant has a heart rate and blood pressure within normal limits.
  • Beta blocker — DRUG
    Selection of the specific BB and initial starting dose will be determined by the treating clinician.
  • Calcium channel blocker — DRUG
    Selection of the specific CCB and initial starting dose will be determined by the treating clinician.

Study Details

To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).

Key Dates

Start date
May 10, 2023
Status verified
Apr 2026
Primary completion
May 30, 2027
Completion
May 30, 2027

Study Design

Enrollment
741 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Beta-Blockers (BB) Therapy
    Participants randomized to this arm will be given a beta-blocker. Specific and appropriate drug selection from the class of beta blockers (i.e. type of BB, dosing, and escalation of dose) will be left to the site clinician in accordance with clinical guidelines. All BB will be administered orally (i.e. pills).
  • Experimental: Calcium Channel Blockers (CCB) Therapy
    Participants randomized to this arm will be given a calcium channel blocker. Specific and appropriate drug selection from the class of calcium channel blockers (i.e. type of CCB, dosing, and escalation of dose) will be left to the site clinician in accordance with clinical guidelines. All CCB will be administered orally (i.e. pills).

Primary Outcome Measure

Change in Quality of Life assessed using EQ-5D-5L [ Time Frame: Baseline and 45 days ]

Central Contacts

Locations (10)

FacilityCityStateZIPSite coordinators
Yale School of MedicineNew HavenConnecticut06520-
Wellstar Research InstituteMariettaGeorgia30060-
Cook County HealthChicagoIllinois60612-
Brigham and Women's HospitalBostonMassachusetts02115-
Mt. Sinai Health SystemNew YorkNew York10029-
Nirvana Integrative MedicineNew YorkNew York10469-
NYC Health and Hospitals, Harlem HospitalNew YorkNew York10037-1802-
Duke University, School of MedicineDurhamNorth Carolina27710-
Cleveland ClinicClevelandOhio44195
Abdulla Damluji, MD
216-630-3297
Inova Health Care ServicesFairfaxVirginia22033-

Find similar trials in New Haven, CT

By research site
Yale School of Medicine· New Haven, CTWellstar Research Institute· Marietta, GACook County Health· Chicago, ILBrigham and Women's Hospital· Boston, MAMt. Sinai Health System· New York, NYNirvana Integrative Medicine· New York, NY

Related Studies